107 related articles for article (PubMed ID: 7781792)
1. Effect of essential fatty acids on natural cytotoxicity in patients with colorectal cancer.
Purasiri P; Ashby J; Heys SD; Eremin O
Eur J Surg Oncol; 1995 Jun; 21(3):254-60. PubMed ID: 7781792
[TBL] [Abstract][Full Text] [Related]
2. Distal procto-colitis, natural cytotoxicity, and essential fatty acids.
Almallah YZ; Richardson S; O'Hanrahan T; Mowat NA; Brunt PW; Sinclair TS; Ewen S; Heys SD; Eremin O
Am J Gastroenterol; 1998 May; 93(5):804-9. PubMed ID: 9625132
[TBL] [Abstract][Full Text] [Related]
3. Modulation in vitro of human natural cytotoxicity, lymphocyte proliferative response to mitogens and cytokine production by essential fatty acids.
Purasiri P; Mckechnie A; Heys SD; Eremin O
Immunology; 1997 Oct; 92(2):166-72. PubMed ID: 9415022
[TBL] [Abstract][Full Text] [Related]
4. Effect of essential fatty acids on circulating T cell subsets in patients with colorectal cancer.
Purasiri P; Ashby J; Heys SD; Eremin O
Cancer Immunol Immunother; 1994 Oct; 39(4):217-22. PubMed ID: 7954523
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-2 (IL-2) augments host cellular immune reactivity in the perioperative period in patients with malignant disease.
Deehan DJ; Heys SD; Ashby J; Eremin O
Eur J Surg Oncol; 1995 Feb; 21(1):16-22. PubMed ID: 7851545
[TBL] [Abstract][Full Text] [Related]
6. The presence and cytotoxicity of CD16+ CD2- subset from PBL and NK cells in long-term IL-2 cultures enhanced by Prothymosin-alpha.
Cordero OJ; Sarandeses C; López-Rodríguez JL; Nogueira M
Immunopharmacology; 1995 Apr; 29(3):215-23. PubMed ID: 7542644
[TBL] [Abstract][Full Text] [Related]
7. Identification of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin 2.
McKenzie RS; Simms PE; Helfrich BA; Fisher RI; Ellis TM
Cancer Res; 1992 Nov; 52(22):6318-22. PubMed ID: 1384959
[TBL] [Abstract][Full Text] [Related]
8. In vivo induction of lymphokine-activated killer cells by interleukin-2 splenic artery perfusion in advanced malignancy.
Klasa RJ; Silver HK; Kong S
Cancer Res; 1990 Aug; 50(16):4906-10. PubMed ID: 2379154
[TBL] [Abstract][Full Text] [Related]
9. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
[TBL] [Abstract][Full Text] [Related]
10. Role of prolactin in the modulation of NK and LAK cell activity after short- or long-term morphine administration in neoplastic patients.
Provinciali M; Di Stefano G; Stronati S; Raffaeli W; Pari G; Fabris N
Int J Immunopharmacol; 1996 Oct; 18(10):577-86. PubMed ID: 9080251
[TBL] [Abstract][Full Text] [Related]
11. A novel multiparametric flow cytometry-based cytotoxicity assay simultaneously immunophenotypes effector cells: comparisons to a 4 h 51Cr-release assay.
Kim GG; Donnenberg VS; Donnenberg AD; Gooding W; Whiteside TL
J Immunol Methods; 2007 Aug; 325(1-2):51-66. PubMed ID: 17617419
[TBL] [Abstract][Full Text] [Related]
12. Natural killer (NK) and lymphokine-activated killer (LAK) activities in a patient who recovered from cancer, and the characteristics of LAK cells generated from CD4-CD8- and CD8+ peripheral blood lymphocytes.
Komatsu F; Kihara K
Clin Immunol Immunopathol; 1995 Oct; 77(1):75-81. PubMed ID: 7554487
[TBL] [Abstract][Full Text] [Related]
13. Reduced LAK cytotoxicity of peripheral blood mononuclear cells in patients with bladder cancer: decreased LAK cytotoxicity caused by a low incidence of CD56+ and CD57+ mononuclear blood cells.
Hermann GG; Petersen KR; Steven K; Zeuthen J
J Clin Immunol; 1990 Nov; 10(6):311-20. PubMed ID: 1707414
[TBL] [Abstract][Full Text] [Related]
14. Fibrin formation inhibits the in vitro cytotoxic activity of human natural and lymphokine-activated killer cells.
Gunji Y; Lewis J; Gorelik E
Blood Coagul Fibrinolysis; 1990 Dec; 1(6):663-72. PubMed ID: 2133246
[TBL] [Abstract][Full Text] [Related]
15. Swainsonine, a glycosylation inhibitor, enhances both lymphocyte efficacy and tumour susceptibility in LAK and NK cytotoxicity.
Galustian C; Foulds S; Dye JF; Guillou PJ
Immunopharmacology; 1994; 27(2):165-72. PubMed ID: 7516929
[TBL] [Abstract][Full Text] [Related]
16. Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer.
Baxevanis CN; Reclos GJ; Gritzapis AD; Dedousis GV; Missitzis I; Papamichail M
Cancer; 1993 Jul; 72(2):491-501. PubMed ID: 8319179
[TBL] [Abstract][Full Text] [Related]
17. Synergistic action of a plant rhamnogalacturonan enhancing antitumor cytotoxicity of human natural killer and lymphokine-activated killer cells: chemical specificity of target cell recognition.
Mueller EA; Anderer FA
Cancer Res; 1990 Jun; 50(12):3646-51. PubMed ID: 1692765
[TBL] [Abstract][Full Text] [Related]
18. LAK-cell-mediated cytotoxicity against tumor cell targets used to monitor the stimulatory effect of interleukin-2: cytotoxicity, target recognition and phenotype of effector cells lysing the Daudi, T24 and K562 tumor cell lines.
Hermann GG; Zeuthen J; Claësson MH
Nat Immun; 1992; 11(1):7-16. PubMed ID: 1611282
[TBL] [Abstract][Full Text] [Related]
19. Human lymphokine-activated killer cells are cytotoxic against cells infected with Toxoplasma gondii.
Subauste CS; Dawson L; Remington JS
J Exp Med; 1992 Dec; 176(6):1511-9. PubMed ID: 1460415
[TBL] [Abstract][Full Text] [Related]
20. NK and LAK activities from human marrow progenitors. I. The effects of interleukin-2 and interleukin-1.
Keever CA; Pekle K; Gazzola MV; Collins NH; Gillio A
Cell Immunol; 1990 Mar; 126(1):211-26. PubMed ID: 1689220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
